Pro Share Advisors LLC Acadia Pharmaceuticals Inc Transaction History

Pro Share Advisors LLC

  • $42.5 Billion
  • Q4 2024

A detailed history of Pro Share Advisors LLC transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, Pro Share Advisors LLC holds 41,580 shares of ACAD stock, worth $617,878. This represents 0.0% of its overall portfolio holdings.

Number of Shares
41,580
Previous 32,416 28.27%
Holding current value
$617,878
Previous $498,000 53.01%
% of portfolio
0.0%
Previous 0.0%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 13, 2025
BUY
$14.29 - $18.76 $130,953 - $171,916
9,164 Added 28.27%
41,580 $762,000
Q3 2024

Nov 13, 2024
BUY
$15.14 - $19.14 $87,660 - $110,820
5,790 Added 21.75%
32,416 $498,000
Q2 2024

Aug 13, 2024
SELL
$14.62 - $18.42 $101,711 - $128,147
-6,957 Reduced 20.72%
26,626 $432,000
Q1 2024

May 08, 2024
BUY
$17.79 - $30.86 $54,223 - $94,061
3,048 Added 9.98%
33,583 $620,000
Q4 2023

Feb 14, 2024
BUY
$20.78 - $31.77 $84,823 - $129,685
4,082 Added 15.43%
30,535 $956,000
Q3 2023

Nov 13, 2023
BUY
$20.84 - $33.47 $3,521 - $5,656
169 Added 0.64%
26,453 $551,000
Q2 2023

Aug 10, 2023
BUY
$17.8 - $25.65 $15,788 - $22,751
887 Added 3.49%
26,284 $629,000
Q1 2023

May 11, 2023
SELL
$16.32 - $20.92 $56,548 - $72,487
-3,465 Reduced 12.01%
25,397 $477,000
Q4 2022

Feb 02, 2023
BUY
$14.2 - $18.63 $28,300 - $37,129
1,993 Added 7.42%
28,862 $459,000
Q3 2022

Nov 04, 2022
SELL
$14.11 - $18.27 $16,071 - $20,809
-1,139 Reduced 4.07%
26,869 $440,000
Q2 2022

Aug 01, 2022
SELL
$13.01 - $27.22 $178,523 - $373,512
-13,722 Reduced 32.88%
28,008 $395,000
Q1 2022

May 10, 2022
SELL
$20.94 - $27.5 $209,588 - $275,247
-10,009 Reduced 19.35%
41,730 $1.01 Million
Q4 2021

Feb 08, 2022
SELL
$16.79 - $27.09 $11,568 - $18,665
-689 Reduced 1.31%
51,739 $1.21 Million
Q3 2021

Nov 12, 2021
SELL
$15.78 - $24.77 $183,521 - $288,075
-11,630 Reduced 18.16%
52,428 $871,000
Q2 2021

Aug 13, 2021
BUY
$19.4 - $27.42 $770,548 - $1.09 Million
39,719 Added 163.19%
64,058 $1.56 Million
Q1 2021

May 14, 2021
SELL
$25.02 - $54.99 $57,020 - $125,322
-2,279 Reduced 8.56%
24,339 $628,000
Q4 2020

Feb 09, 2021
SELL
$41.04 - $56.79 $32,134 - $44,466
-783 Reduced 2.86%
26,618 $1.42 Million
Q3 2020

Nov 13, 2020
BUY
$36.42 - $57.0 $24,328 - $38,076
668 Added 2.5%
27,401 $1.13 Million
Q2 2020

Aug 03, 2020
SELL
$39.26 - $52.73 $121,509 - $163,199
-3,095 Reduced 10.38%
26,733 $1.3 Million
Q1 2020

May 15, 2020
SELL
$31.65 - $46.87 $678,132 - $1 Million
-21,426 Reduced 41.8%
29,828 $1.26 Million
Q4 2019

Feb 12, 2020
SELL
$36.21 - $51.4 $84,333 - $119,710
-2,329 Reduced 4.35%
51,254 $2.19 Million
Q3 2019

Nov 12, 2019
SELL
$22.22 - $44.01 $71,503 - $141,624
-3,218 Reduced 5.67%
53,583 $1.93 Million
Q2 2019

Aug 13, 2019
SELL
$23.32 - $28.12 $207,408 - $250,099
-8,894 Reduced 13.54%
56,801 $1.52 Million
Q1 2019

May 15, 2019
BUY
$16.17 - $27.38 $67,833 - $114,859
4,195 Added 6.82%
65,695 $1.76 Million
Q4 2018

Feb 14, 2019
SELL
$14.32 - $22.92 $71,027 - $113,683
-4,960 Reduced 7.46%
61,500 $994,000
Q3 2018

Nov 14, 2018
SELL
$13.03 - $21.81 $17,108 - $28,636
-1,313 Reduced 1.94%
66,460 $1.38 Million
Q2 2018

Aug 13, 2018
BUY
$15.07 - $22.34 $114,471 - $169,694
7,596 Added 12.62%
67,773 $1.04 Million
Q1 2018

May 14, 2018
SELL
$22.47 - $32.33 $210,903 - $303,449
-9,386 Reduced 13.49%
60,177 $1.35 Million
Q4 2017

Feb 14, 2018
SELL
$26.84 - $39.14 $45,144 - $65,833
-1,682 Reduced 2.36%
69,563 $2.1 Million
Q3 2017

Nov 13, 2017
BUY
$29.49 - $38.37 $194,634 - $253,241
6,600 Added 10.21%
71,245 $2.68 Million
Q2 2017

Aug 11, 2017
BUY
N/A
64,645
64,645 $1.8 Million

Others Institutions Holding ACAD

# of Institutions
322
Shares Held
165M
Call Options Held
855K
Put Options Held
350K
View Full List

About ACADIA PHARMACEUTICALS INC

ACAD Quotes by TradingView
  • Ticker ACAD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 161,843,008
  • Market Cap $2.4B
  • Description
  • ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...
More about ACAD
Track This Portfolio

Track Pro Share Advisors LLC Portfolio

Follow Pro Share Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Share Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Share Advisors LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email